EPITARGET
Targets and biomarkers for antiepileptogenesis
| Coordinatore | LUNDS UNIVERSITET
Organization address
address: Paradisgatan 5c contact info |
| Nazionalità Coordinatore | Sweden [SE] |
| Sito del progetto | http://www.epitarget.eu |
| Totale costo | 15˙740˙584 € |
| EC contributo | 11˙999˙975 € |
| Programma | FP7-HEALTH
Specific Programme "Cooperation": Health |
| Code Call | FP7-HEALTH-2013-INNOVATION-1 |
| Funding Scheme | CP-IP |
| Anno di inizio | 2013 |
| Periodo (anno-mese-giorno) | 2013-11-01 - 2018-10-31 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 |
LUNDS UNIVERSITET
Organization address
address: Paradisgatan 5c contact info |
SE (LUND) | coordinator | 1˙653˙000.00 |
| 2 |
UNIVERSITY COLLEGE LONDON
Organization address
address: GOWER STREET contact info |
UK (LONDON) | participant | 1˙162˙860.00 |
| 3 |
Nome Ente NON disponibile
Organization address
address: YLIOPISTONRANTA 1 E contact info |
FI (Kuopio) | participant | 1˙045˙000.00 |
| 4 |
TO-BBB TECHNOLOGIES BV
Organization address
address: JH OORTWEG 19 contact info |
NL (LEIDEN) | participant | 744˙541.00 |
| 5 |
ISTITUTO DI RICERCHE FARMACOLOGICHE MARIO NEGRI
Organization address
address: Via Giuseppe La Masa 19 contact info |
IT (MILANO) | participant | 687˙500.00 |
| 6 |
IMPERIAL COLLEGE OF SCIENCE, TECHNOLOGY AND MEDICINE
Organization address
address: SOUTH KENSINGTON CAMPUS EXHIBITION ROAD contact info |
UK (LONDON) | participant | 672˙599.00 |
| 7 |
Academisch Medisch Centrum bij de Universiteit van Amsterdam
Organization address
address: MEIBERGDREEF 9 contact info |
NL (AMSTERDAM) | participant | 645˙480.00 |
| 8 |
UNIVERSITAETSKLINIKUM BONN
Organization address
address: Sigmund-Freud-Strasse 25 contact info |
DE (BONN) | participant | 642˙000.00 |
| 9 |
GABO:MI GESELLSCHAFT FUR ABLAUFORGANISATION:MILLIARIUM MBH & CO KG GAB O
Organization address
address: Oskar-von-Miller-Ring 29 contact info |
DE (MUENCHEN) | participant | 590˙800.00 |
| 10 |
UNIVERSITE D'AIX MARSEILLE
Organization address
address: Boulevard Charles Livon 58 contact info |
FR (Marseille) | participant | 530˙540.00 |
| 11 |
STIFTUNG TIERAERZTLICHE HOCHSCHULE HANNOVER
Organization address
address: BUNTEWEG 2 contact info |
DE (HANNOVER) | participant | 523˙620.00 |
| 12 |
LIFE AND BRAIN GMBH
Organization address
address: SIGMUND FREUD STR 25 contact info |
DE (BONN) | participant | 500˙000.00 |
| 13 |
MICROVITAE TECHNOLOGIES SAS
Organization address
address: AVENUE D ARMENIE POLO D ACTIVITE Y MORANDAT 1480 contact info |
FR (GARDANNE) | participant | 495˙300.00 |
| 14 |
UNIVERSITA DEGLI STUDI DI FERRARA
Organization address
address: SAVONAROLA 9 contact info |
IT (FERRARA) | participant | 475˙000.00 |
| 15 |
BIOVIRON SARL
Organization address
address: RUE MARCELIN BERTHELOT 5 contact info |
FR (CHASSIEU) | participant | 473˙100.00 |
| 16 |
MEDIZINISCHE HOCHSCHULE HANNOVER
Organization address
address: Carl-Neuberg-Strasse 1 contact info |
DE (HANNOVER) | participant | 406˙655.00 |
| 17 |
BEN-GURION UNIVERSITY OF THE NEGEV
Organization address
address: Office of the President - Main Campus contact info |
IL (BEER SHEVA) | participant | 399˙980.00 |
| 18 |
INSTYTUT BIOLOGII DOSWIADCZALNEJ IM. M. NENCKIEGO POLSKIEJ AKADEMII NAUK
Organization address
address: UL. LUDWIKA PASTEURA 3 contact info |
PL (WARSZAWA) | participant | 352˙000.00 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
'Epilepsy is a devastating condition affecting over 50 million people worldwide. This multidisciplinary project is focused on the process leading to epilepsy, epileptogenesis, in adults. Our main hypothesis is that there are combinations of various causes, acting in parallel and/or in succession, that lead to epileptogenesis and development of seizures. Our central premise and vision is that a combinatorial approach is necessary to identify appropriate biomarkers and develop effective antiepileptogenic therapeutics. The project will focus on identifying novel biomarkers and their combinations for epileptogenesis after potentially epileptogenic brain insults in clinically relevant animal models, such as traumatic brain injury (TBI) and status epilepticus (SE); explore multiple basic mechanisms of epileptogenesis and their mutual interactions related to cell degeneration, circuit reorganization, inflammatory processes, free radical formation, altered neurogenesis, BBB dysfunction, genetic and epigenetic alterations; and translating these findings towards the clinic by validating biomarkers identified from animal models in human post TBI brain tissue and blood samples, post-mortem brain tissue in individuals that died soon after SE, and human brain and blood samples from chronic epilepsy cases. The project will identify novel combinatorial biomarkers and novel disease-modifying combinatorial treatment strategies for epileptogenesis, create an Epilepsy Preclinical Biobank, and validate translational potential of results from animal models in human tissue. To adequately address the proposed goals, the project will develop technological breakthroughs, such as completely novel chemogenetic approaches, novel MRI techniques, novel multimodal organic recording devices for simultaneous recordings of EEG / cellular unit activity and biochemical measurements, novel bioluminescence for in vivo promoter activity analysis, and novel systems biology approaches.'
Introduzione (Teaser)
Epilepsy is a devastating condition affecting over 50 million people worldwide. An EU consortium is using a combinatorial approach to identify biomarkers and develop antiepileptogenic therapeutics.